Naltrexone in the treatment of opioid-dependent pregnant women: The case for a considered and measured approach to research

Addiction

Volumn 108, Issue 2, 2013, Pages 233-247

  Jones, Hendrée E ^a,b   Chisolm, Margaret S ^b   Jansson, Lauren M ^b   Terplan, Mishka ^c  

^a RTI INTERNATIONAL   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

Naltrexone; Opioids; Pregnancy

Indexed keywords

BUPRENORPHINE; METHADONE; NALTREXONE; NARCOTIC AGENT; NARCOTIC ANTAGONIST;

FEMALE; HUMAN; METHODOLOGY; NEWBORN; OPIATE ADDICTION; OPIATE SUBSTITUTION TREATMENT; PREGNANCY; PREGNANCY COMPLICATION; REVIEW; RISK ASSESSMENT; RISK FACTOR; TREATMENT OUTCOME; WITHDRAWAL SYNDROME; NEONATAL ABSTINENCE SYNDROME; OPIOID-RELATED DISORDERS; PREGNANCY COMPLICATIONS; PROCEDURES;

BUPRENORPHINE; FEMALE; HUMANS; INFANT, NEWBORN; METHADONE; NALTREXONE; NARCOTIC ANTAGONISTS; NARCOTICS; NEONATAL ABSTINENCE SYNDROME; OPIATE SUBSTITUTION TREATMENT; OPIOID-RELATED DISORDERS; PREGNANCY; PREGNANCY COMPLICATIONS; RISK ASSESSMENT; RISK FACTORS; TREATMENT OUTCOME;

EID: 84872512579     PISSN: 09652140     EISSN: 13600443     Source Type: Journal    
DOI: 10.1111/j.1360-0443.2012.03811.x     Document Type: Article

References (104)

1. European Monitoring Centre for Drugs and Drug Addiction (EMCDDA). EMCDDA. A gender perspective on drug use and responding to drug problems. Luxembourg: Office for the Official Publications of the European Communities; 2006.
2. Substance Abuse and Mental Health Services Administration (SAMHSA). Results from the 2009 National Survey on Drug Use and Health: Volume I. Summary of National Findings. Rockville, MD: SAMHSA; 2010.
3. Armstrong K. A., Kennedy M. G., Kline A., Tunstall C. Reproductive health needs: comparing women at high, drug-related risk of HIV with a national sample. J Am Med Womens Assoc 1999; 54: 65-70, 8.
4. Substance Abuse and Mental Health Services Administration (SAMHSA). Results from the 2008 National Survey on Drug Use and Health: National findings. Office of Applied Studies, HHS Publication no. SMA 09-4434. Rockville, MD: SAMHSA; 2009.
5. Collins G., McAllister M. Combating abuse and diversion of prescription opiate medications. Psychiatr Ann 2006; 36: 410-6.
6. Lifschitz M. H., Wilson G. S., Smith E. O., Desmond M. M. Factors affecting head growth and intellectual function in children of drug addicts. Pediatrics 1985; 75: 269-74.
7. Lester B. M., Andreozzi L., Appiah L. Substance use during pregnancy: time for policy to catch up with research. Harm Reduct J 2004; 1: 5.
8. Alroomi L. G., Davidson J., Evans T. J., Galea P., Howat R. Maternal narcotic abuse and the newborn. Arch Dis Child 1988; 63: 81-3.
9. Connaughton J. F., Reeser D., Finnegan L. P. Pregnancy complicated by drug addiction. In: Bolognese R., Schwartz R., editors. Perinatal Medicine: Management of the High Risk Fetus and Neonate. Baltimore: Williams & Wilkins; 1977, p. 259-72.
10. Glass L., Evans H. E. Narcotic withdrawal in the newborn. Am Fam Physician 1972; 6: 75-8.
11. Hulse G. K., Milne E., English D. R., Holman C. D. The relationship between maternal use of heroin and methadone and infant birth weight. Addiction 1997; 92: 1571-9.
12. Kandall S. R., Albin S., Gartner L. M., Lee K. S., Eidelman A., Lowinson J. The narcotic-dependent mother: fetal and neonatal consequences. Early Hum Dev 1977; 1: 159-69.
13. Messinger D. S., Bauer C. R., Das A., Seifer R., Lester B. M., Lagasse L. L. etal. The maternal lifestyle study: cognitive, motor, and behavioral outcomes of cocaine-exposed and opiate-exposed infants through three years of age. Pediatrics 2004; 113: 1677-85.
14. Naeye R. L., Blanc W., Leblanc W., Khatamee M. A. Fetal complications of maternal heroin addiction: abnormal growth, infections, and episodes of stress. J Pediatr 1973; 83: 1055-61.
15. American Academy of Pediatrics Committee on Drugs. Neonatal drug withdrawal. Pediatrics 1998; 101: 1079-88.
16. Myers B. J., Britt G. C., Lodder D. E., Kendall K. A., Williams-Petersen M. G. Effects of cocaine exposure on infant development: a review. J Child Fam Stud 1992; 1: 393-415.
17. Food and Drug Administration (FDA)/New Drug Application (NDA) Guidance. State methadone maintenance treatment guidelines. Rockville, MD: US Department of Health and Human Services, Substance Abuse and Mental Health Services Administration, Center for Substance Abuse Treatment; 1992.
18. Jones H. E., O'Grady K. E., Malfi D., Tuten M. Methadone maintenance versus methadone taper during pregnancy: maternal and neonatal outcomes. Am J Addict 2008; 17: 372-86.
19. Kissin W. B., Svikis D. S., Moylan P., Haug N. A., Stitzer M. L. Identifying pregnant women at risk for early attrition from substance abuse treatment. J Subst Abuse Treat 2004; 27: 31-8.
20. Geber W. F., Schramm L. C. Congenital malformations of the central nervous system produced by narcotic analgesics in the hamster. Am J Obstet Gynecol 1975; 123: 705-13.
21. Jurand A. Teratogenic activity of methadone hydrochloride in mouse and chick embryos. J Embryol Exp Morphol 1973; 30: 449-58.
22. Finnegan L. P., Kaltenbach K. Neonatal abstinence syndrome. In: Hoekelman R. A., Friedman S. B., Nelson N. M., Seidel H. M., editors. Primary Pediatric Care, 2nd edn. St Louis, MO: Mosby; 1992, p. 1367-78.
23. Jansson L. M., Velez M., Harrow C. Methadone maintenance and lactation: a review of the literature and current management guidelines. J Hum Lact 2004; 20: 62-71.
24. Jansson L. M., Dipietro J. A., Elko A., Velez M. Infant autonomic functioning and neonatal abstinence syndrome. Drug Alcohol Depend 2010; 109: 198-204.
25. Wachman E. M., Byun J., Philipp B. L. Breastfeeding rates among mothers of infants with neonatal abstinence syndrome. Breastfeed Med 2010; 5: 159-64.
26. Walsh S. L., Eissenberg T. The clinical pharmacology of buprenorphine: extrapolating from the laboratory to the clinic. Drug Alcohol Depend 2003; 70: S13-27.
27. REPROTOX. http://www.reprotox.org. 2011. (accessed 4 March 2011). (Archived at http://www.webcitation.org/65kMVHwKy on 26 February 2012).
28. Mori N., Sakanoue M., Kamata S., Takeuchi M., Shimpo K., Tamagawa M. Toxicological studies of buprenorphine. II. Teratogenicity in rat. Iyakuhin Kenkyu 1982; 13: 509-31.
29. Mori N., Sakanoue M., Kamata S., Takeuchi M., Shimpo K., Tamagawa M. Buprenorphine: toxicological studies of buprenorphine. III. Perinatal and postnatal study in rat. Iyakuhin Kenkyu 1982; 13: 532-44.
30. Kahila H. Substance misuse problems during pregnancy with special emphasis on buprenorphine. http://urn.fi/URN:ISBN:ISBN978-952-10-7204-8. (accessed 22 March 2012). (Archived at http://www.webcitation.org/66LckqSKt on 22 March 2012).
31. Minozzi S., Amato L., Vecchi S., Davoli M. Maintenance agonist treatments for opiate dependent pregnant women. Cochrane Database Syst Rev 2008; (2): CD006318.
32. Jones H. E., Johnson R. E., Jasinski D. R., O'Grady K. E., Chisholm C. A., Choo R. E. etal. Buprenorphine versus methadone in the treatment of pregnant opioid-dependent patients: effects on the neonatal abstinence syndrome. Drug Alcohol Depend 2005; 79: 1-10.
33. Lejeune C., Simmat-Durand L., Gourarier L., Aubisson S. Prospective multicenter observational study of 260 infants born to 259 opiate-dependent mothers on methadone or high-dose buprenophine substitution. Drug Alcohol Depend 2006; 82: 250-7.
34. Fischer G., Ortner R., Rohrmeister K., Jagsch R., Baewert A., Langer M. etal. Methadone versus buprenorphine in pregnant addicts: a double-blind, double-dummy comparison study. Addiction 2006; 101: 275-81.
35. Kakko J., Heilig M., Sarman I. Buprenorphine and methadone treatment of opiate dependence during pregnancy: comparison of fetal growth and neonatal outcomes in two consecutive case series. Drug Alcohol Depend 2008; 96: 69-78.
36. Czerkes M., Blackstone J., Pulvino J. Buprenorphine versus methadone treatment for opiate addiction in pregnancy: an evaluation of neonatal outcomes. San Francisco, CA; American College of Obstetricians and Gynecologists; 2010.
37. Jones H. E., Kaltenbach K., Heil S. H., Stine S. M., Coyle M. G., Arria A. M. etal. Neonatal abstinence syndrome after methadone or buprenorphine exposure. N Engl J Med 2010; 363: 2320-31.
38. Food and Drug Administration. Letter to Akermes, Inc. 2010. Available at: http://www.accessdata.fda.gov/drugsatfda_docs/appletter/2010/021897s015ltr.pdf (accessed 4 March 2011). (Archived at http://www.webcitation.org/65kMsTxAf on 26 February 2012).
39. Martin W. R., Jasinski D. R., Mansky P. A. Naltrexone, an antagonist for the treatment of heroin dependence. Effects in man. Arch Gen Psychiatry 1973; 28: 784-91.
40. Jaffe J. H., Martin W. R. Opioid analgesics and antagonists. In: Gilman A. G., Rall T. W., Niels A. S., Taylor P., editors. Goodman & Gilman's: The Pharmacological Basis of Therapeutics, 8th edn. New York: Pergamon; 1990, p. 485-521.
41. Kleber H. D., Kosten T. R., Gaspari J., Topazian M. Nontolerance to the opioid antagonism of naltrexone. Biol Psychiatry 1985; 20: 66-72.
42. Comer S. D., Sullivan M. A., Hulse G. K. Sustained-release naltrexone: novel treatment for opioid dependence. Expert Opin Invest Drugs 2007; 16: 1285-94.
43. Gonzalez J. P., Brogden R. N. Naltrexone. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in the management of opioid dependence. Drugs 1988; 35: 192-213.
44. Kirchmayer U., Davoli M., Verster A. D., Amato L., Ferri A., Perucci C. A. A systematic review on the efficacy of naltrexone maintenance treatment in opioid dependence. Addiction 2002; 97: 1241-9.
45. Kleber H. D. Pharmacologic treatments for heroin and cocaine dependence. Am J Addict 2003; 12: S5-18.
46. Modesto-Lowe V., Van Kirk J. Clinical uses of naltrexone: a review of the evidence. Exp Clin Psychopharmacol 2002; 10: 213-27.
47. Rea F., Bell J. R., Young M. R., Mattick R. P. A randomised, controlled trial of low dose naltrexone for the treatment of opioid dependence. Drug Alcohol Depend 2004; 75: 79-88.
48. Krupitsky E. M., Zvartau E. E., Masalov D. V., Tsoi M. V., Burakov A. M., Egorova V. Y. etal. Naltrexone for heroin dependence treatment in St. Petersburg, Russia. J Subst Abuse Treat 2004; 26: 285-94.
49. Minozzi S., Amato L., Vecchi S., Davoli M., Kirchmayer U., Verster A. Oral naltrexone maintenance treatment for opioid dependence. Cochrane Database Syst Rev 2011; (2): CD001333.
50. Rothenberg J. L., Sullivan M. A., Church S. H., Seracini A., Collins E., Kleber H. D. etal. Behavioral naltrexone therapy: an integrated treatment for opiate dependence. J Subst Abuse Treat 2002; 23: 351-60.
51. Gibson A. E., Degenhardt L. J., Hall W. D. Opioid overdose deaths can occur in patients with naltrexone implants. Med J Aust 2007; 186: 152-3.
52. Digiusto E., Shakeshaft A., Ritter A., O'Brien S., Mattick R. P. Serious adverse events in the Australian National Evaluation of Pharmacotherapies for Opioid Dependence (NEPOD). Addiction 2004; 99: 450-60.
53. Comer S. D., Collins E. D., Kleber H. D., Nuwayser E. S., Kerrigan J. H., Fischman M. W. Depot naltrexone: long-lasting antagonism of the effects of heroin in humans. Psychopharmacology (Berl) 2002; 159: 351-60.
54. Everly J. J., Umbricht A., Fingerhood M., Bigelow G., Silverman K. Employment-based reinforcement of acceptance of depot naltrexone injections in opioid-dependent adults. San Juan, PR: Annual Meeting of the College on the Problems of Drug Dependence; 2008.
55. Lobmaier P., Kornor H., Kunoe N., Bjorndal A. Sustained-release naltrexone for opioid dependence. Cochrane Database Syst Rev 2008; (2): CD006140.
56. Krupitsky E., Zvartau E., Woody G. Use of naltrexone to treat opioid addiction in a country in which methadone and buprenorphine are not available. Curr Psychiatry Rep 2010; 12: 448-53.
57. Food and Drug Administration. Vivitrol. Food and Drug Administration. 2011 (accessed 2 April 2011). (Archived at http://www.webcitation.org/65kNdiMdK on 26 February 2012).
58. O'Brien C., Cornish J. W. Naltrexone for probationers and parolees. J Subst Abuse Treat 2006; 31: 107-11.
59. Tait R. J., Hulse G. K. Hospital morbidity associated with the natural history of heroin use. J Opioid Manag 2008; 4: 321-7.
60. Sullivan M. A., Garawi F., Bisaga A., Comer S. D., Carpenter K., Raby W. N. etal. Management of relapse in naltrexone maintenance for heroin dependence. Drug Alcohol Depend 2007; 91: 289-92.
61. Center for Substance Abuse Treatment. Pregnant substance-using women: treatment improvement protocol #2. Rockville, MD: Substance Abuse and Mental Health Services Administration; 1993.
62. White J. M., Irvine R. J. Future directions in opioid overdose. Addiction 1999; 94: 978-80.
63. Schuh K. J., Walsh S. L., Stitzer M. L. Onset, magnitude and duration of opioid blockade produced by buprenorphine and naltrexone in humans. Psychopharmacology (Berl) 1999; 145: 162-74.
64. Dalayeun J. F., Nores J. M., Bergal S. Physiology of beta-endorphins. A close-up view and a review of the literature. Biomed Pharmacother 1993; 47: 311-20.
65. Sander H. W., Gintzler A. R. Spinal cord mediation of the opioid analgesia of pregnancy. Brain Res 1987; 408: 389-93.
66. Gintzler A. R. Endorphin-mediated increases in pain threshold during pregnancy. Science 1980; 210: 193-5.
67. Chan C. F., Page-Sharp M., Kristensen J. H., O'Neil G., Ilett K. F. Transfer of naltrexone and its metabolite 6, beta-naltrexol into human milk. J Hum Lact 2004; 20: 322-6.
68. Zagon I. S., Tobias S. W., Hytrek S. D., McLaughlin P. J. Opioid receptor blockade throughout prenatal life confers long-term insensitivity to morphine and alters mu opioid receptors. Pharmacol Biochem Behav 1998; 59: 201-7.
69. Nuite J. A., Smith S., Kennedy G. L., Keplinger M. L., Calandra J. C. Reproductive, teratogenic, perinatal and postnatal studies with cyclazocine. Toxicol Appl Pharmacol 1975; 31: 534-43.
70. Christian M. S. Reproductive toxicity and teratology evaluations of naltrexone. J Clin Psychiatry 1984; 45: 7-10.
71. Zagon I. S., McLaughlin P. J. An overview of the neurobehavioral sequelae of perinatal opioid exposure. In: Yanai J., editor. Neurobehavioral Teratology. New York: Elsevier Science Publishers; 1984, p. 197-234.
72. McLaughlin P. J., Tobias S. W., Lang C. M., Zagon I. S. Chronic exposure to the opioid antagonist naltrexone during pregnancy: maternal and offspring effects. Physiol Behav 1997; 62: 501-8.
73. Farid W. O., Dunlop S. A., Tait R. J., Hulse G. K. The effects of maternally administered methadone, buprenorphine and naltrexone on offspring: review of human and animal data. Curr Neuropharmacol 2008; 6: 125-50.
74. Tegeder I., Geisslinger G. Opioids as modulators of cell death and survival-unraveling mechanisms and revealing new indications. Pharmacol Rev 2004; 56: 351-69.
75. McLaughlin P. J., Tobias S. W., Lang C. M., Zagon I. S. Opioid receptor blockade during prenatal life modifies postnatal behavioral development. Pharmacol Biochem Behav 1997; 58: 1075-82.
76. Zagon I. S., McLaughlin P. J. Opioid growth factor (OGF) inhibits anchorage-independent growth in human cancer cells. Int J Oncol 2004; 24: 1443-8.
77. McLaughlin P. J., Wylie J. D., Bloom G., Griffith J. W., Zagon I. S. Chronic exposure to the opioid growth factor, [Met5]-enkephalin, during pregnancy: maternal and preweaning effects. Pharmacol Biochem Behav 2002; 71: 171-81.
78. Vorhees C. V. Effects of prenatal naloxone exposure on postnatal behavioral development of rats. Neurobehav Toxicol Teratol 1981; 3: 295-301.
79. Zagon I. S., McLaughlin P. J. Naltrexone modulates body and brain development in rats: a role for endogenous opioid systems in growth. Life Sci 1984; 35: 2057-64.
80. Sedlacek J. Opioid elements in development of the spontaneous motility of chick embryos. Physiol Bohemoslov 1986; 35: 427-36.
81. Harry G. J., Rosecrans J. A. Behavioral effects of perinatal naltrexone exposure: a preliminary investigation. Pharmacol Biochem Behav 1979; 11 (Suppl): 19-22.
82. Cohen E., Keshet G., Shavit Y., Weinstock M. Prenatal naltrexone facilitates male sexual behavior in the rat. Pharmacol Biochem Behav 1996; 54: 183-8.
83. Caba M., Poindron P., Krehbiel D., Levy F., Romeyer A., Venier G. Naltrexone delays the onset of maternal behavior in primiparous parturient ewes. Pharmacol Biochem Behav 1995; 52: 743-8.
84. Hetta J., Terenius L. Prenatal naloxone affects survival and morphine sensitivity of rat offspring. Neurosci Lett 1980; 16: 323-7.
85. Hulse G. K., O'Neill G., Pereira C., Brewer C. Obstetric and neonatal outcomes associated with maternal naltrexone exposure. Aust NZ J Obstet Gynaecol 2001; 41: 424-8.
86. Hulse G., O'Neil G. Using naltrexone implants in the management of the pregnant heroin user. Aust NZ J Obstet Gynaecol 2002; 42: 569-73.
87. Hulse G. K., Arnold-Reed D. E., O'Neil G., Hansson R. C. Naltrexone implant and blood naltrexone levels over pregnancy. Aust NZ J Obstet Gynaecol 2003; 43: 386-8.
88. Hulse G. K., O'Neill G. A possible role for implantable naltrexone in the management of the high-risk pregnant heroin user. Aust NZ J Obstet Gynaecol 2002; 42: 93-4.
89. Hulse G. K., O'Neil G., Arnold-Reed D. E. Methadone maintenance versus implantable naltrexone treatment in the pregnant heroin user. Int J Gynaecol Obstet 2004; 85: 170-1.
90. Volavka J., Bauman J., Pevnick J., Reker D., James B., Cho D. Short-term hormonal effects of naloxone in man. Psychoneuroendocrinology 1980; 5: 225-34.
91. Mendelson J. H., Mello N. K., Cristofaro P., Skupny A., Ellingboe J. Use of naltrexone as a provocative test for hypothalamic-pituitary hormone function. Pharmacol Biochem Behav 1986; 24: 309-13.
92. Gindoff P. R., Jewelewicz R., Hembree W., Wardlaw S., Ferin M. Sustained effects of opioid antagonism during the normal human luteal phase. J Clin Endocrinol Metab 1988; 66: 1000-4.
93. Bart G., Borg L., Schluger J. H., Green M., Ho A., Kreek M. J. Supressed prolactin response to dunorphin A1-13 in methadone-maintained versus control subjects. J Pharmacol Exp Ther 2003; 306: 581-7.
94. Kreek M. J. Medical complications in methadone patients. Ann NY Acad Sci 1978; 311: 110-34.
95. Wodak A. D., Ali R., Henry D., Sansom L. Ensuring the safety of new medications and devices: are naltrexone implants safe? Med J Aust 2008; 188: 438-9.
96. Dugosh K. L., Festinger D. S., Croft J. R., Marlowe D. B. Measuring coercion to participate in research within a doubly vulnerable population: initial development of the coercion assessment scale. J Empir Res Hum Res Ethics 2010; 5: 93-102.
97. Coverdale J. H., McCullough L. B., Chervenak F. A. The ethics of randomized placebo-controlled trials of antidepressants with pregnant women: a systematic review. Obstet Gynecol 2008; 112: 1361-8.
98. Lyerly A. D., Little M. O., Faden R. R. A critique of the 'fetus as patient'. Am J Bioeth 2008; 8: 42-4; discussion W4-6.
99. Kandall S. R., Albin S., Lowinson J., Berle B., Eidelman A. I., Gartner L. M. Differential effects of maternal heroin and methadone use on birthweight. Pediatrics 1976; 58: 681-5.
100. Connaughton J. F., Reeser D., Schut J., Finnegan L. P. Perinatal addiction: outcome and management. Am J Obstet Gynecol 1977; 129: 679-86.
101. Lurie P., Wolfe S. M. Unethical trials of interventions to reduce perinatal transmission of the human immunodeficiency virus in developing countries. N Engl J Med 1997; 337: 853-6.
102. Terplan M., Wright T. The effects of cocaine and amphetamine use during pregnancy on the newborn: myth versus reality. J Addict Dis 2011; 30: 1-5.
103. Bandstra E. S., Morrow C. E., Mansoor E., Accornero V. H. Prenatal drug exposure: infant and toddler outcomes. J Addict Dis 2010; 29: 245-58.
104. Pluess M., Belsky J. Prenatal programming of postnatal plasticity? Dev Psychopathol 2011; 23: 29-38.